Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Zhang, Li ^a   Xu, Jiaoya ^a   Song, Haiyan ^a   Yao, Zemin ^b   Ji, Guang ^a,c  

^a LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b UNIVERSITY OF OTTAWA   (Canada)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Hepatosteatosis; Insulin resistance; Salvia Nelumbinis naturalis

Indexed keywords

ALANINE AMINOTRANSFERASE; ARTEMISIA SCOPARIA EXTRACT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FAT; GLUCOSE; GLYCOGEN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LEPTIN; LIPID; MESSENGER RNA; NELUMBO NUCIFERA EXTRACT; PIOGLITAZONE; PLANT EXTRACT; POLYGONUM CUSPIDATUM EXTRACT; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; SALVIA MILTIORRHIZA EXTRACT; SIMVASTATIN; SUCROSE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HERBACEOUS AGENT; JIANGZHI;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTEMISIA SCOPARIA; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CHINESE MEDICINE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; DYSLIPIDEMIA; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLEPTINEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LIPID STORAGE; LIVER FUNCTION; LIVER PARENCHYMA; LIVER WEIGHT; MALE; NELUMBO NUCIFERA; NONHUMAN; POLYGONUM CUSPIDATUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SALVIA MILTIORRHIZA; SIGNAL TRANSDUCTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; INSULIN RESISTANCE; LIVER; METABOLISM; PHYTOTHERAPY; SALVIA; WISTAR RAT;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; FATTY LIVER; HEP G2 CELLS; HUMANS; INSULIN RESISTANCE; LIVER; MALE; PHYTOTHERAPY; RATS; RATS, WISTAR; SALVIA;

EID: 84910095428     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0236-8     Document Type: Article

References (44)

1. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009, 104(4):861-867. 10.1038/ajg.2009.67, 19293782.
2. Janczyk W, Socha P. Non-alcoholic fatty liver disease in children. Clin Res Hepatol Gastroenterol 2012, 36(3):297-300. 10.1016/j.clinre.2012.03.026, 22521558.
3. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007, 91(6):1125-1149. ix, 10.1016/j.mcna.2007.06.001, 17964913.
4. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008, 93(11 Suppl 1):S74-S80. 10.1210/jc.2008-1399, 18987273.
5. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006, 91(12):4753-4761. 10.1210/jc.2006-0587, 16968800.
6. Previs SF, Withers DJ, Ren JM, White MF, Shulman GI. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem 2000, 275(50):38990-38994. 10.1074/jbc.M006490200, 10995761.
7. Bowman TA, Ramakrishnan SK, Kaw M, Lee SJ, Patel PR, Golla VK, Bourey RE, Haram PM, Koch LG, Britton SL, Wisloff U, Lee AD, Najjar SM. Caloric restriction reverses hepatic insulin resistance and steatosis in rats with low aerobic capacity. Endocrinology 2010, 151(11):5157-5164. 10.1210/en.2010-0176, 20861239.
8. Wang M, Sun S, Wu T, Zhang L, Song H, Hao W, Zheng P, Xing L, Ji G. Inhibition of LXRalpha/SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule. Evid Based Complement Alternat Med 2013, 2013:584634. 23762146.
9. LU Y-L WANGM, ZHANG L, HE Y-Q YANGL, WANG C-H, WANG Z-T JIG. Simultaneous Determination of Six Components in the 'Jiang-Zhi' Granule by UPLC-MS Analysis. Chin J Nat Med 2010, 8(6):449-455.
10. Qi Z, Xue J, Zhang Y, Wang H, Xie M. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced Fatty liver rats. Planta Med 2011, 77(3):231-235. 10.1055/s-0030-1250268, 20717873.
11. Lomba A, Milagro FI, Garcia-Diaz DF, Marti A, Campion J, Martinez JA. Obesity induced by a pair-fed high fat sucrose diet: methylation and expression pattern of genes related to energy homeostasis. Lipids Health Dis 2010, 9:60. 10.1186/1476-511X-9-60, 20534152.
12. Fernandes-Santos C, Evangelista Carneiro R, De Souza ML, Barbosa Aguila M, Mandarim-de-Lacerda CA. Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. Pancreas 2009, 38(3):e80-e86. 10.1097/MPA.0b013e3181987d9d, 19214135.
13. Song HY, Zhang L, Pan JL, Yang LL, Ji G. Bioactivity of five components of Chinese herbal formula Jiangzhi granules against hepatocellular steatosis. J Integr Med 2013, 11(4):262-268. 10.3736/jintegrmed2013034, 23867244.
14. Lima CR, Vasconcelos CF, Costa-Silva JH, Maranhao CA, Costa J, Batista TM, Carneiro EM, Soares LA, Ferreira F, Wanderley AG. Anti-diabetic activity of extract from Persea americana Mill. leaf via the activation of protein kinase B (PKB/Akt) in streptozotocin-induced diabetic rats. J Ethnopharmacol 2012, 141(1):517-525. 10.1016/j.jep.2012.03.026, 22472105.
15. Villanueva CJ, Monetti M, Shih M, Zhou P, Watkins SM, Bhanot S, Farese RV. Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology 2009, 50(2):434-442. 10.1002/hep.22980, 19472314.
16. Xing LJ, Zhang L, Liu T, Hua YQ, Zheng PY, Ji G. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol 2011, 668(3):467-471. 10.1016/j.ejphar.2011.07.036, 21839075.
17. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004, 24(12):5434-5446. 10.1128/MCB.24.12.5434-5446.2004, 15169905.
18. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002, 277(44):42394-42398. 10.1074/jbc.C200444200, 12228220.
19. Considine RV, Nyce MR, Allen LE, Morales LM, Triester S, Serrano J, Colberg J, Lanza-Jacoby S, Caro JF. Protein kinase C is increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus: an alteration not due to hyperglycemia. J Clin Invest 1995, 95(6):2938-2944. 10.1172/JCI118001, 7769136.
20. Pan J, Wang M, Song H, Wang L, Ji G. The efficacy and safety of traditional chinese medicine (jiang zhi granule) for nonalcoholic Fatty liver: a multicenter, randomized, placebo-controlled study. Evid Based Complement Alternat Med 2013, 2013:965723. 24369486.
21. Fon Tacer K, Rozman D. Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids 2011, 2011:783976. 10.1155/2011/783976, 21773052.
22. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 2010, 45(10):907-914. 10.1007/s11745-010-3408-1, 20524075.
23. Poss J, Custodis F, Werner C, Weingartner O, Bohm M, Laufs U. Cardiovascular disease and dyslipidemia: beyond LDL. Curr Pharm Des 2011, 17(9):861-870. 10.2174/138161211795428858, 21418031.
24. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002, 35(4):898-904. 10.1053/jhep.2002.32527, 11915037.
25. Ota T, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest 2008, 118(1):316-332. 10.1172/JCI32752, 18060040.
26. Day CP, James OF. Steatohepatitis: a tale of two "hits" ?. Gastroenterology 1998, 114(4):842-845. 10.1016/S0016-5085(98)70599-2, 9547102.
27. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):370-379. 10.1055/s-0028-1091981, 18956293.
28. Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, Gude F, Cadarso-Suarez C, Garcia F, De Francisco A. Insulin resistance index (HOMA-IR) levels in a general adult population: curves percentile by gender and age. The EPIRCE study. Diabetes Res Clin Pract 2011, 94(1):146-155. 10.1016/j.diabres.2011.07.015, 21824674.
29. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001, 24(3):539-548. 10.2337/diacare.24.3.539, 11289482.
30. Ben Djoudi Ouadda A, Levy E, Ziv E, Lalonde G, Sane AT, Delvin E, Elchebly M. Increased hepatic lipogenesis in insulin resistance and Type 2 diabetes is associated with AMPK signalling pathway up-regulation in Psammomys obesus. Biosci Rep 2009, 29(5):283-292. 10.1042/BSR20080141, 18842111.
31. Zheng D, Ionut V, Mooradian V, Stefanovski D, Bergman RN. Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes 2009, 58(2):352-359. 10.2337/db08-0875, 19011168.
32. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008, 7(2):125-134. 10.1016/j.cmet.2007.11.013, 18249172.
33. Farese RV, Zechner R, Newgard CB, Walther TC. The Problem of Establishing Relationships between Hepatic Steatosis and Hepatic Insulin Resistance. Cell Metab 2012, 15(5):570-573. 10.1016/j.cmet.2012.03.004, 22560209.
34. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42(5):987-1000. 10.1002/hep.20920, 16250043.
35. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006, 103(4):1006-1011. 10.1073/pnas.0506982103, 16410358.
36. Ros S, Garcia-Rocha M, Calbo J, Guinovart JJ. Restoration of hepatic glycogen deposition reduces hyperglycaemia, hyperphagia and gluconeogenic enzymes in a streptozotocin-induced model of diabetes in rats. Diabetologia 2011, 54(10):2639-2648. 10.1007/s00125-011-2238-x, 21811873.
37. Ha Do T, Trung TN, Hien TT, Dao TT, Yim N, Ngoc TM, Oh WK, Bae K. Selected compounds derived from Moutan Cortex stimulated glucose uptake and glycogen synthesis via AMPK activation in human HepG2 cells. J Ethnopharmacol 2010, 131(2):417-424. 10.1016/j.jep.2010.07.010, 20633632.
38. Schmitz-Peiffer C, Biden TJ. Protein kinase C function in muscle, liver, and beta-cells and its therapeutic implications for type 2 diabetes. Diabetes 2008, 57(7):1774-1783. 10.2337/db07-1769, 18586909.
39. Hribal ML, D'Alfonso R, Giovannone B, Lauro D, Liu YY, Borboni P, Federici M, Lauro R, Sesti G. The sulfonylurea glimepiride regulates intracellular routing of the insulin-receptor complexes through their interaction with specific protein kinase C isoforms. Mol Pharmacol 2001, 59(2):322-330. 11160869.
40. McCowen KC, Fajtova VT. Pioglitazone for diabetes prevention. N Engl J Med 2011, 365(2):182-183. author reply 183-184, 10.1056/NEJMc1104572, 21751926.
41. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135(4):1176-1184. 10.1053/j.gastro.2008.06.047, 18718471.
42. Kusunoki M, Tsutsumi K, Sato D, Nakamura A, Habu S, Mori Y, Morishita M, Yonemoto T, Miyata T, Nakaya Y, Nakamura T. Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886. Eur J Pharmacol 2011, 668(3):486-491. 10.1016/j.ejphar.2011.07.030, 21835171.
43. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, Nash CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362(18):1675-1685. 10.1056/NEJMoa0907929, 20427778.
44. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298(10):1180-1188. 10.1001/jama.298.10.1180, 17848652.